BioSpace News Archive

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce positive preclinical data from their ALPHA-0602 ALS gene therapy program.

Covalon Technologies Ltd., an advanced medical technologies company, is pleased to announce that the Company’s Board of Directors has approved the grant of stock options exercisable for a total of 507,500 common shares to certain of its directors, officers, employees, and consultants.

Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations, announced that the companies are unveiling Xpert Alliance, a joint visualization of their strategic collaboration.

Owens & Minor, Inc. (NYSE: OMI), a leading global healthcare solutions company, today announced that it has closed the previously announced acquisition of Apria, Inc.

Fluidigm Corporation announced that it has entered into a support agreement with Caligan Partners LP, Fluidigm’s current largest holder of common stock, under which Caligan has agreed to vote “FOR” all Fluidigm proposals related to the proposed strategic capital infusion transaction with Casdin Capital, LLC and Viking Global Investors LP at Fluidigm’s Special Meeting of Stockholders, which has been adjourned and will reconvene on April 1, 2022.

Medical device company Baymatob has completed a placement of A$4.215 million, with proceeds used to continue in-human clinical trials for its AI-guided labor monitoring device, Oli.

O’Brien Medical is pleased to announce the publication of a key research study validating the performance of its premier product, the ETF, in the prediction of diabetic foot ulcers (DFUs).

Company will use HindSight grant to conduct a clinical study that seeks to reduce alert fatigue Dascena has received a grant from the National Institute of Health to conduct a clinical study that evaluates the efficacy of its HindSight algorithm to accurately and efficiently predict the onset of sepsis in patients.

The endoscopy devices market is predicted to grow at a CAGR 7.5% during the forecast period and to reach over US$ 67.37 billion by 2027, according to Precedence Research.

“I am pleased to announce the submission of our AcuVid™ COVID-19 Rapid Antigen Saliva Test for U.S. Food & Drug Administration’s Emergency Use Authorization,” shared Rob Fia, CEO of Therma Bright.